The ceramide synthase family, often referred to as LASS (longevity assurance homologs), encompasses a group of enzymes crucial in sphingolipid metabolism. These enzymes are responsible for the synthesis of ceramides, a type of lipid molecule that plays a key role in cell membrane integrity and signaling pathways. Each ceramide synthase isoform (CerS1-6 in humans) prefers different fatty acyl-CoA substrates, leading to the production of ceramides with distinct acyl chain lengths. The ceramides synthesized by these enzymes are involved in various cellular processes, including apoptosis, cell proliferation, and stress response. Dysregulation of ceramide synthase activity is linked to numerous diseases, including cancer, neurodegenerative disorders, and metabolic conditions. Additionally, ceramides act as signaling molecules, influencing pathways like inflammation and cell survival, and are integral to the formation of lipid rafts in cell membranes.
Targeting ceramide synthase (LASS) for disruption or inhibition using small molecules is a strategic approach for understanding its biological functions and implications in diseases. By selectively inhibiting specific isoforms of ceramide synthase, researchers can elucidate the distinct roles of different ceramide species in cellular processes. Small molecule inhibitors allow for precise modulation of ceramide levels, facilitating studies on how changes in ceramide synthesis affect cellular signaling pathways. This approach is critical for dissecting the complex sphingolipid metabolism pathways and their impact on cell physiology. Inhibiting ceramide synthase can reveal insights into the mechanisms of diseases like cancer, where ceramide levels are often dysregulated.
Siehe auch...
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | ¥2256.00 ¥7672.00 | 18 | |
Ein Inhibitor der Ceramid-Synthase, der die Aktivität von LASS4 durch kompetitive Hemmung der Funktion des Enzyms verringern kann. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | ¥2290.00 ¥6893.00 | 24 | |
Dieser nicht-kompetitive Inhibitor der neutralen Sphingomyelinase könnte den Ceramidspiegel beeinflussen, der die LASS4-Expression reguliert. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | ¥8123.00 | ||
Ein Farnesyltransferase-Inhibitor, der möglicherweise die posttranslationale Modifikation von Proteinen beeinflusst, die LASS4 regulieren. | ||||||
Ceranib-2 | 1402830-75-4 | sc-507503 | 10 mg | ¥1952.00 | ||
Ein spezifischer Inhibitor der Ceramid-Synthase, der die Aktivität von LASS4 durch direkte Hemmung verringern kann. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | ¥1895.00 | ||
Ein Autophagie-Inhibitor, der den Umsatz zellulärer Komponenten einschließlich LASS4 beeinflussen kann. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | ¥745.00 ¥1320.00 | 6 | |
Hemmt die saure Sphingomyelinase und könnte zu einem veränderten Sphingolipid-Stoffwechsel führen, der sich möglicherweise auf LASS4 auswirkt. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | ¥2764.00 | 9 | |
Hemmt die Phosphatidylcholin-spezifische Phospholipase C, wodurch der Sphingomyelinabbau und damit auch der Ceramidspiegel, der LASS3 beeinflussen kann, beeinträchtigt wird. | ||||||
SKI II | 312636-16-1 | sc-204286 sc-204286A | 10 mg 50 mg | ¥1083.00 ¥4513.00 | 3 | |
Hemmt die Sphingosin-Kinase, was den Sphingosin-1-Phosphat-Spiegel und die Ceramid-Synthese beeinflussen kann, was sich möglicherweise auf LASS3 auswirkt. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | ¥1173.00 ¥3554.00 | ||
Induziert die Ceramid-Synthese und beeinflusst möglicherweise die LASS3-Aktivität durch Rückkopplungsmechanismen. | ||||||
Sphingomyelin | 85187-10-6 | sc-201381 sc-201381A | 100 mg 500 mg | ¥2031.00 ¥6318.00 | 3 | |
Blockiert die Ceramid-Synthase, einschließlich LASS3, was zu einer verringerten Ceramid-Synthese führt. | ||||||